Member Info for crumbs

I always thought that was just Chippers kitchen

Certainly an interesting day today and very hard to say what pattern is developing here but seems most want to be in than out and why.... Scancell is part of the UK Gov backed Covid vaccine race...scancell are expected to do a MaB deal soon... scancell have a pipeline that could potentially fill a pharma and with moditope very well may have a huge goose that lays massive golden eggs... and maybe most importantly for AIM scancell is not skint at the moment so in desperate need of keep lights on funds or likely to bought out at 23p either lol

Well done Chester

I think the delivery would be the clincher for a deal...
We know all pharma want to do what they can in this Covid crisis... mostly that involves them going through all their catalogue of drugs looking for anything that may do something... Others have their own vaccines and then there is the partnering route well scancell have a product with form and backing science that is growing and now it has Gov funding too...

Strings not string....What we know is it is very likely a deal on one MaB is likely to be concluded in the coming days / weeks...
But with as many strings as scancell have the potential is for many deals on all platforms with many products and multiple potential targets.... I agree with nana a major pharma could make a move in on Covidity at any moment... I'm sure there is interest there.

1. Closer than yesterday
2. When a deal is closed

haha indeed there are certainly far worse risks but if that is the worst I can live with it... too early to be attaching figures to it too... but glad to see after this little rapid jump up to 18p seems to have stop talk of scancell having to accept 23p in a buyout :))

Yes nana.... that was my thinking on saying if moditope and I know scancell is more than moditope but... anyways if it is then Redmile well want to take their reward and be out but bigger players would then move in... infact for Redmile it would be an interesting situation that they maybe have never been in .... invested at 5.5p in what may be showing to be the biggest class of onco immunotherapy ... let us hope it gets to that situation lol

Boom yes it is good enough for me too and you're right it is now up to scancell to deliver but they must have seen enough in the first place to willing to take on the risk.....I get what you are saying- they have no intention of sticking around forever and may well not even 2 years...

The truth is ... we do not know what is the preferred exit for Remile and Vulpes or even if they are on the same page there (you would think they are) all we know is they want a return they are happy with... Of course, I know that scenario of the company being bought out at a price Redmile/Vulpes like and we have no control over is a real possibility but I would think we have a ways to be getting there like I say I think we are at least going to be getting modi1 results in a lot will depend on does moditope translate into trial success ... Some far bigger players could be getting involved then on success or on less clear results we accept what comes....I doubt they are all in for one MaB deal anyways lol

Do Redmile and Vulpes have to have a defined exit strategy? Obviously like us all they are in for a return but I doubt they have a solid set in stone strategy I'm sure they review all the time and plan with what is happening in their investments and what may happen and their own needs....I would think at the very least they will want to see moditope (modi1) go through trial as that is what the bulk f their investment will be spent on?

Forgive us new poster :)

' drawbacks to their platforms/patents.'....What The hell! :)

Well, Cars that is what makes a market.... that there are so many trades here daily now is great to say the interest has returned it was not too long ago when we had days of not a single trade... Also though now we are attracting traders... I reckon a few of those may well also be buying in and not selling completely out on a gain... stake builders as any one who does even 5 mins research or watches the proactive vid knows this share has legs and is poised to leap at any moment.

WTP indeed! I'm not even sure I'd trade after say the first MaB deal RNS... as well there could be at least 2 more of the same on the way after those, plus... BioNTech TCR that can appear anytime... and more funds to Covidity or a pharma partner coming in on it and modi1 gets a partner for its trial... and.... well there are just so many potentials lol.... So my mindset is if it drops below my average I'm back to nibbling but whilst it is above I'll just enjoy the ride as I'm happy that my 250k could one day make enough for an early retirement all going well :)

Yeah like I say fair enough I would trade some of mine too but not at the moment as it's taken me long enough to get the 250k I have lol and I'd like to keep that amount now, it is one of those psychological things.....maybe if it was 255k i'd be trading the 5k and feel fine with that risk :) ...

That is why I have not bothered trading any as this moment in time I feel the risk is too high for me as the RNS of a deal would pop up the moment a sold some to trade lol... but well done to all who are having success ...I more focus my mind on I wonder what position we may be this time next year... I was surprised at this rise we have had not as I think it is undeserved or that the market ought to wake up to the potential here but to my mind I felt it would not wake up until a deal was done and only then might we have seen a big rise.... bodes well for when positive newsflow does hit though..... the redmile effect seems to have attracted the renewed interest here and I suppose the Covidity funding too....

We know Seattle Genetics are aware and indeed may have played some part in the R&D of scancells MaBs
'The aim of my PhD project was to generate novel anti-glycan monoclonal antibodies against tumours. During my PhD I had generated three mAbs, of which two of them had been granted a patent. We collaborated with university research groups and companies such as Seattle Genetics, OMT and Invivogen to look for the potential clinical usage of our mAbs. For e.g., ADC and generation of human antibody. These three mAbs are potent direct cancer cell killers. In addition to ADCC and CDC, the antibodies also cause direct cytotoxicity to cancer cells. '

'This will be to see if they generated any antibodies from the immunization that also attack the brain or spinal cord tissue.

If scientists ascertain the vaccine caused the volunteer to suffer transverse myelitis, the arm may be permanently paused.

Schaffner says it's unclear whether the experimental vaccine or the placebo caused this side effect, but the longer the investigation, the more suspicion builds.

'I would have thought if this patient received the placebo, this would have been a really brief assessment: "Oh well, this is a placebo. Can't have anything to do with the vaccine. Open the trial again,"' he said.

'But the longer this goes on, the longer the suspicion that the patient had received the vaccine becomes more evident because this is exactly the kind of aberrant immune response that would be a concern for any vaccine, and this one in particular.' '
https://www.dailymail.co.uk/health/article-8735235/US-regulators-concerned-effects-AstraZenecas-vaccine.html

Yeah basically it is what we said yesterday but there in the black and white of an RNS from a seller.... they have taken a profit after a long time of being in the red but kept a big core holding as they know what could come...